Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vanda Pharmaceuticals (VNDA) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Q3 2025 value amounting to 55.07%.

  • Vanda Pharmaceuticals' EBITDA Margin fell 324400.0% to 55.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 56.6%, marking a year-over-year decrease of 374100.0%. This contributed to the annual value of 20.0% for FY2024, which is 132400.0% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its EBITDA Margin stood at 55.07% for Q3 2025, which was down 324400.0% from 72.71% recorded in Q2 2025.
  • Vanda Pharmaceuticals' 5-year EBITDA Margin high stood at 18.72% for Q2 2021, and its period low was 81.53% during Q1 2025.
  • In the last 5 years, Vanda Pharmaceuticals' EBITDA Margin had a median value of 12.2% in 2022 and averaged 12.94%.
  • In the last 5 years, Vanda Pharmaceuticals' EBITDA Margin skyrocketed by 166600bps in 2021 and then tumbled by -625000bps in 2025.
  • Quarter analysis of 5 years shows Vanda Pharmaceuticals' EBITDA Margin stood at 13.25% in 2021, then decreased by -19bps to 10.72% in 2022, then tumbled by -242bps to 15.22% in 2023, then decreased by -24bps to 18.83% in 2024, then tumbled by -192bps to 55.07% in 2025.
  • Its last three reported values are 55.07% in Q3 2025, 72.71% for Q2 2025, and 81.53% during Q1 2025.